Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Malignant pleural effusion (MPE) significantly impairs patient quality of life and prognosis.
• Current MPE management is primarily palliative, highlighting the need for effective therapeutic strategies.

Purpose of the Study:

• To investigate the potential of methotrexate-packaging tumor cell-derived microparticles (MTX-MP) as an immunotherapeutic agent for MPE.
• To elucidate the mechanism by which MTX-MP treatment mobilizes and activates neutrophils against MPE.

Main Methods:

• Perfusion of MTX-MP via a pleural catheter in MPE patients.
• Analysis of neutrophil recruitment via macrophage-released CXCL1 and CXCL2.
• Ex vivo assessment of neutrophil activation, reactive oxygen species (ROS) and neutrophil extracellular trap (NET) release.
• In vitro and in vivo (tumor-bearing mice) evaluation of NETs in sealing endothelium and resolving MPE.

Main Results:

• MTX-MP perfusion successfully recruited neutrophils in MPE patients.
• Recruited neutrophils exhibited activation, releasing ROS and NETs to induce tumor cell death.
• Neutrophil-derived NETs demonstrated efficacy in sealing damaged endothelium, facilitating MPE resolution in vitro and in vivo.

Conclusions:

• MTX-MP serve as an effective immunotherapeutic agent for MPE by activating neutrophil-mediated anti-tumor responses.
• Cell-derived microparticles offer a promising drug-packaging strategy for cancer immunotherapy.
• This approach presents a novel therapeutic avenue for managing malignant pleural effusion.